| Ruth Blum, MD | |
|
801 N 29th St, Billings, MT 59101-0905 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Ruth Blum |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Experience | 9 Years |
| Location | 801 N 29th St, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588058168 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 302734 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Frances Mahon Deaconess Hospital | Glasgow, MT | Hospital |
| Beartooth Billings Clinic | Red lodge, MT | Hospital |
| Stillwater Billings Clinic | Columbus, MT | Hospital |
| Rosebud Health Care Center | Forsyth, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
News Archive
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.
Christina Andrews, associate professor of health services policy and management at the University of South Carolina's Arnold School of Public Health and an expert on addiction treatment will lead a study funded by the National Institute of Alcohol Abuse and Alcoholism to examine the effectiveness of Medicaid-covered alcohol use disorder treatment.
The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 4 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326104845 PECOS PAC ID: 6002993516 Enrollment ID: O20080430000212 |
News Archive
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.
Christina Andrews, associate professor of health services policy and management at the University of South Carolina's Arnold School of Public Health and an expert on addiction treatment will lead a study funded by the National Institute of Alcohol Abuse and Alcoholism to examine the effectiveness of Medicaid-covered alcohol use disorder treatment.
The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ruth Blum, MD Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | Ruth Blum, MD 801 N 29th St, Billings, MT 59101-0905 Ph: (406) 238-2500 |
News Archive
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.
Christina Andrews, associate professor of health services policy and management at the University of South Carolina's Arnold School of Public Health and an expert on addiction treatment will lead a study funded by the National Institute of Alcohol Abuse and Alcoholism to examine the effectiveness of Medicaid-covered alcohol use disorder treatment.
The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.
› Verified 4 days ago
Dr. Robert E Stockdale, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N, Ste 503e, Billings, MT 59101 Phone: 406-237-5400 Fax: 406-237-5420 | |
Dr. Michael Oliver Hickman Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N Ste 503e, Billings, MT 59101 Phone: 406-233-7540 | |
Dr. Daniel Holst, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Daniel Loren Faaborg, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N Ste 500e, Billings, MT 59101 Phone: 406-237-5400 | |
Dr. Karin Emilia Brown, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-435-8784 | |
Richard B. Melzer, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Lisa Barnett Bland, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |